Genentech moving away from Caremark

Bergen Brunswig accounted for 14% of Genentech sales in 1999 ($200 mil.), up from 11% in 1998. Cardinal represented 13% of sales ($180 mil.), up from 11%. Caremark represented less than 10% of revenues in 1999, down from 10% in 1998 and 14% in 1997. The change in part reflects the diminishing importance of human growth hormone to Genentech. At its peak, an exclusive growth hormone supply agreement with Caremark represented more than 25% of Genentech revenues